Tech IPOs, public-market debuts, and what each one means for the exit environment.
SpaceX shares fell as much as 6% and dropped below their $135 IPO price after 319 million more shares became tradable, erasing roughly $103B of the company's implied market value in a single day.
Space-infrastructure company Gravitics set terms for a $125M Nasdaq listing via reverse merger, aiming to build private space station modules despite zero revenue and a $24.5M six-month net loss.
Rebellions' CFO calls a Korea Exchange listing the company's top priority, even as Nvidia opens early talks about a possible investment in or acquisition of the same $2.3B AI chipmaker.
Defense startup Castelion raised a $1B Series C co-led by Andreessen Horowitz, Carlyle and JPMorgan at a $13B valuation to mass-produce hypersonic missiles in New Mexico, as the Pentagon races to close a stockpile gap with China.
Airwallex is repositioning from cross-border payments into an AI-native financial operating system focused on autonomous finance, while president Lucy Liu says it still targets IPO-readiness by year-end.
OpenAI CFO Sarah Friar told employees at an all-hands meeting the company will be public by 2027 or sooner, framing the IPO as a fundraising milestone rather than a finish line, while acknowledging Anthropic could go public first.
OpenAI CFO Sarah Friar told an all-hands that the company 'will be a public company in 2027' or sooner if growth keeps inflecting, and said Anthropic listing first is 'no problem' since OpenAI is 'running our own race.'
Up to 84 million Cerebras Class B shares become eligible to convert and sell by the end of August, about 2.4 times the 34.5 million shares sold in its IPO, with another 87 million unlocking in September and October.
ServiceNow's stock fell 42% in early 2026 on fears AI agents would make enterprise software obsolete, but its $7.75B acquisition of cybersecurity startup Armis helped drive a 41% May rally and outperformance versus Salesforce and Workday.
Sequoia Capital, Khosla Ventures and Y Combinator top the list of investors backing 2026's new unicorns, with 250 companies reaching billion-dollar valuations through August 15 -- up from 193 in all of 2025, per Crunchbase data.
Unitree Robotics surged as much as 629% in its Shanghai debut, briefly hitting a $66B valuation before settling up 460% at roughly $47B, becoming the first humanoid robot maker listed in mainland China.
Defense-tech roll-up Lyntris priced its IPO at $17.50 a share, below the $19-$22 target range, raising roughly $297.5 million ahead of its NYSE debut under ticker LYNX -- a real-time gut check on defense-tech IPO demand after weeks of bullish sector coverage.
Peacock raised prices across all tiers for the fourth time in four years, months after posting its first quarterly profit of $189 million in adjusted EBITDA, with the ad-free plan going from $17 to $20 a month.
Fort Robotics, a Mark Cuban-backed safety-infrastructure company for autonomous machines, agreed to go public via SPAC at a $557 million enterprise value -- the first public company built specifically for physical-AI safety.
With AMD and Google narrowing Nvidia's technology lead, the company is deploying its balance sheet instead -- a $500 billion GPU financing pact with Wall Street, a $105 billion OpenAI backstop and $30.2 billion in equity holdings.
Tesla is planning a public launch of the Cybercab in Austin as soon as this month, according to The Information, though the two-seater without a steering wheel or pedals has often been spotted testing with both installed.
Tactical Resources began trading on the Nasdaq under ticker TREO on August 18 via a SPAC merger with Plum Acquisition Corp. III, positioning the company to process rare-earth tailings in Texas as US critical-minerals policy intensifies.
Kraken's Krak money app launched a US debit card paying up to 2% back in cash or bitcoin, spendable from more than 600 currencies and crypto assets converted at the point of purchase.
SpaceX recovered an intact Starship after a 24-day tow across the Indian Ocean to Christmas Island, the first time a ship survived splashdown without disintegrating and the first chance to inspect flown heat shield hardware.
Karman Line Acquisition Corp and NorthStrive Acquisition Corp I priced a combined $300 million in blank-check IPOs targeting aerospace, defense and industrial manufacturing.
Pony AI reported Q2 revenue up 69% to $36.2 million, with robotaxi service revenue up 691% to a record $12.1 million as its fleet grew to 2,000 vehicles and Uber committed to more than 4,000 robotaxis across international markets including Europe.
European Central Bank economists wrote that research on past technological revolutions points to a likely correction in current stock valuations, with the drawdown arriving whether or not investors are being irrational about AI.
South Korean retail investors made $4.5 billion in net purchases of US securities in July, part of $73.6 billion in 2025 alone, as domestic market volatility pushes 'ant investors' toward US equities and leveraged semiconductor ETFs.
Memory chipmaker CXMT overtook Tencent as China's most valuable listed company just weeks after a 466% IPO debut, putting a number on how central memory chips have become to China's AI buildout.
OpenAI's revenue run-rate has topped $40 billion, roughly double where it stood at the end of 2025, sharpening the case for its Wall Street debut even as the risks Pulse flagged in its IPO warning coverage remain unresolved.
The 2026 tech listing boom is real in aggregate and concentrated in practice: a handful of megacap names carry the volume while the median venture-backed company still cannot clear the bar underwriters are setting.
Stripe's $7 billion purchase of OpenRouter, SpaceX's Cursor deal and consolidation among eVTOL makers point to strategic acquisition replacing the public offering as the primary liquidity path for AI-era companies.
Reddit joins the S&P 500 before markets open on August 18, becoming only the second pure-play social media company in the index after Meta, following a stock rally triggered by the inclusion announcement.
Eight S-1-family filings hit the SEC between August 13 and 17, and none are venture-scale tech debuts -- a reminder that most weeks in an active IPO year still produce shell registrations and small financials, not headline listings.
SpaceX's $1.77 trillion June debut made Q2 2026 the biggest quarter for U.S. IPOs on record, and OpenAI and Anthropic are both racing toward their own public listings before year-end -- the two biggest names left in a pipeline that's otherwise thinning out.
A cooler-than-expected inflation report and Intel upsized $20 billion stock sale helped push the odds of a Fed hold at the September meeting to 67%, up from 55%, a backdrop that matters for how pending mega-IPOs get priced this fall.
A hot IPO window doesn't guarantee a hot stock afterward -- Cerebras is down sharply on its second earnings report even after raising guidance, while Reddit and SanDisk show post-listing performance hinges on execution, not debut pricing.
SEC data shows traditional US IPOs raised roughly $114.1 billion through June 30, more than seven times the $14.8 billion raised over the same period in 2025, spread across AI infrastructure, industrials, healthcare and consumer sectors.
Anthropic investors are modeling a $2 trillion IPO valuation for October, with some projecting as high as $3 trillion, based on annualized revenue expected to reach $100 billion to $120 billion by year-end.
SharonAI Holdings, an Australian neocloud operator partnering with Nvidia on GPU clusters, filed an amended S-1 registering $691.7 million in convertible notes and 26 million resale shares as it builds out AI data center capacity.
In August, Anthropic was reported to be preparing a listing that could value it near $2 trillion as soon as October. That date did not hold: it filed a public S-1 on October 26 and an amended S-1 on November 2, still without a price range, and trading could start November 16-18 at the earliest, Yahoo Finance reported.
At least six companies filed IPO paperwork with the SEC on August 12, spanning AI infrastructure, biopharma, fintech and minerals -- a reminder the listing pipeline stays busy behind mega-IPO headlines like Anthropic's.
Unitree's STAR Market IPO subscription window closed Wednesday after pricing at 150.80 yuan a share and a $9 billion valuation, with the humanoid robot maker's Shanghai trading debut now expected between August 17 and 21.
Robinhood Ventures Fund II, a closed-end fund giving retail investors exposure to 80 early-stage startups linked to Y Combinator, closes its share-request window August 12 ahead of a planned NYSE debut at $25 a share on August 13.
Londian Wason New Energy Tech, a Shenzhen-based electrolytic copper foil producer for EV batteries, set terms to raise $75 million on the NYSE under ticker FOIL, with pricing expected around August 12.
BlossomHill and Latigo Biotherapeutics both closed upsized IPOs by August 10, capping a four-deal stretch that also included Braveheart Bio and Attovia Therapeutics pricing above or near the top of their ranges.
Unitree's Shanghai STAR Market IPO subscription formally opened at a roughly $9 billion valuation, the first profitable, scaled humanoid robotics company to go public on a major exchange.
Attovia Therapeutics priced an upsized $289 million IPO and climbed 29% on debut, the fourth biotech in two weeks to price well above its original terms.
Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.
BillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.
BofA's Bull & Bear indicator hit 9.7, its highest since 2021 and above the firm's own 8.0 sell threshold — a trace's-take on what that extreme reading should change about how GPs mark portfolio companies against public comps.
BlossomHill and Braveheart Bio both upsized and priced above their original ranges this week, the clearest two-deal signal yet that the biotech IPO window -- closed to all but the strongest names in 2024-2025 -- is reopening.
Latigo Biotherapeutics priced its upsized IPO at $18 a share for $345.6 million and jumped 17% in its Nasdaq debut, the third biotech offering in two weeks to price above range.
A weak July jobs report sent stocks to a broad rally on rate-cut bets, with Atlassian and Twilio posting blowout earnings beats -- even as Bank of America's own sentiment gauge hit its most bullish reading since 2021.
SpaceX stock fell 8% after a Q2 earnings beat spooked investors on capex, then rallied 15.83% three days later as its first lockup expiration passed without heavy selling and the Cursor deal stayed on track.
Bank of America's Bull & Bear sentiment indicator jumped to 9.7 -- its highest reading since 2021 and above the firm's own 8.0 sell-signal threshold -- even as the S&P 500 and Nasdaq both rallied Friday on weak jobs data.
Atlassian shares surged as much as 35.6% after fiscal Q4 revenue beat estimates by $100M+ on 31% cloud growth, with co-founder Mike Cannon-Brookes pledging to personally buy up to $250M of stock.
Cloudflare shares jumped as much as 17% after beating Q2 estimates and raising full-year guidance, with AI-driven demand for network security and infrastructure cited as the key growth driver.
BlossomHill Therapeutics priced an upsized IPO at $16 a share for $150M and began trading on Nasdaq under BLSM, more than 50% above the $100M target Pulse flagged when the company first filed.
Braveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.
SpaceX shares are trading near $108, down more than half from their post-IPO high, just as the first of four straight monthly unlock events begins -- a live case study for OpenAI and Anthropic on what happens once lockups start expiring.
Unitree Robotics priced its Shanghai STAR Market IPO at 150.80 yuan a share, raising roughly $904 million and valuing China's first publicly traded humanoid robot maker at about $9 billion.
SK Hynix fell nearly 10% and Samsung dropped over 6% as Asian tech stocks tracked a Wall Street AI-name selloff, the second sharp chip-sector drop in the Korean chipmaker's shares in two weeks.
Vogenx priced 6.25M shares at $12 to raise roughly $68M net, funding development of mizagliflozin, an SGLT1 inhibitor for gastrointestinal and metabolic disorders, through 2028.
Braveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.
